Literature DB >> 10480301

Effects of combined emergency percutaneous cardiopulmonary support and reperfusion treatment in patients with refractory ventricular fibrillation complicating acute myocardial infarction.

K Nagao1, N Hayashi, K Arima, K Ooiwa, K Kikushima, T Anazawa, J Ohtsuki, K Kanmatsuse.   

Abstract

OBJECT: We conducted a prospective study to determine whether or not combined emergency percutaneous cardiopulmonary support (PCPS) and coronary reperfusion treatment are useful for acute myocardial infarction (MI) patients with unsynchronized electric shock-resistive ventricular fibrillation (VF). PATIENTS AND METHODS: Thirty-two acute MI patients who lapsed into the refractory VF were entered into the study. Group 1 consisted of 19 patients with VF outside the hospital, and Group 2 consisted of 13 patients with VF immediately after arrival at the hospital. The primary endpoint was successful reperfusion, return of spontaneous circulation and good recovery without neurologic disability.
RESULTS: The infarct-related arteries showed a significant difference between Groups 1 and 2. However, the two groups had similar rates of successful reperfusion (84.6% vs 94.7%, respectively) and return of spontaneous circulation (89.5% vs 84.6%, respectively). The rates of good recovery were similarly low in both groups (5.3% vs 15.4%, respectively).
CONCLUSION: Combined emergency PCPS and reperfusion treatment produced high return of spontaneous circulation, however the neurologic outcome was low.

Entities:  

Mesh:

Year:  1999        PMID: 10480301     DOI: 10.2169/internalmedicine.38.710

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  1 in total

1.  End-tidal carbon dioxide monitoring indicates recovery from cardiogenic shock in patients receiving percutaneous cardiopulmonary support.

Authors:  Takuji Yoshida; Masazumi Watanabe; Mikiko Murakami; Hitoshi Furukawa; Hideki Nakahara
Journal:  J Artif Organs       Date:  2005       Impact factor: 1.731

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.